Secretome landed $30 million in Series A funding<\/a>\u00a0from RA Capital Management, the round\u2019s sole investor, to advance STM-01 toward pivotal Phase 2 and Phase 3 development in Duchenne muscular dystrophy, an indication with few disease-modifying therapies. Founded in Baltimore in 2018, Secretome moved its headquarters to Plano in 2023. The company also maintains a presence at BioLabs at Pegasus Park in Dallas.<\/p>\nA Sarepta veteran takes the CMO seat<\/p>\n
Singh has more than 30 years of experience in clinical development, regulatory strategy and rare disease drug development. Most recently, he led clinical development at Sarepta Therapeutics, where he directed programs for innovative therapies. Previously, he held positions of increasing responsibility in cell and gene therapy development at Sanofi\/Genzyme.<\/p>\n
Building commercial infrastructure<\/p>\n
Chapman will build the commercial and operational infrastructure to support Secretome\u2019s development programs as the company grows. With more than three decades of leadership experience in the U.S. and Europe, Chapman has expertise in commercial strategy, market access, launching products and organizational buildout. He has held senior executive and commercial roles at Zambon USA, Agios Pharmaceuticals, AMAG\/COVIS, Reata Pharmaceuticals, Boehringer Ingelheim and Pfizer.<\/p>\n
Chapman has been a part of more than 20 product launches that include rare diseases, hematology, pulmonary, cardiovascular, neurology and other specialty therapeutic areas. He also has expertise in business development, alliance management and government affairs.<\/p>\n
Two decades in the DMD ecosystem<\/p>\n
Lucas has more than 20 years of biotechnology experience spanning medical affairs, scientific communications, CMC development and stakeholder engagement. Previously, Lucas has held leadership positions at Sarepta Therapeutics, Biogen Idec, Cardinal Health and Biotech Primer. Her work in the DMD ecosystem includes scientific education, medical affairs leadership and engagement with healthcare providers, researchers and patient advocacy organizations. She worked on the development and launch of four products.<\/p>\n
Finance, HR and corporate planning<\/p>\n
Loeffler will guide financial operations, corporate planning, human resources, accounting and administrative infrastructure for Secretome. With more than two decades of experience in biopharma finance and accounting leadership, she has experience with several capital raises, an IPO, a reverse merger and SEC reporting. Previously, she held senior finance leadership roles at Reata Pharmaceuticals and Reneo Pharmaceuticals (now OnKure Therapeutics), and began her career in public accounting at Ernst & Young.<\/p>\n
Smith moves to development<\/p>\n
In addition to these appointments, Smith has transitioned into the role of Chief Development Officer. As chief development officer, Smith will lead Secretome\u2019s regenerative cell therapy pipeline in cardioimmunology. She directed the company\u2019s first-in-human study of STM-01 as chief medical officer. With extensive biotechnology and regenerative medicine experience, she previously served in leadership roles at SQZ Biotechnologies, Viracta Therapeutics, Atara Biotherapeutics, Gilead Sciences and Amgen. Her expertise spans clinical development, inflammation, cardiovascular disease, rare diseases and advanced cell therapies.<\/p>\n
Don\u2019t miss what\u2019s next. Subscribe\u00a0to\u00a0Dallas\u00a0Innovates.<\/p>\n
Track Dallas-Fort Worth\u2019s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.<\/p>\n
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Secretome Therapeutics\u2019 leadership team includes, from left: David Chapman, senior vice president of operations; Karin Lucas, Ph.D., vice…\n","protected":false},"author":2,"featured_media":397783,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[133482,139643,73187,139644,14172,160,162,161,139645],"class_list":["post-397782","post","type-post","status-publish","format-standard","has-post-thumbnail","category-plano","tag-biotechnology","tag-cell-therapy","tag-duchenne-muscular-dystrophy","tag-executive-appointments","tag-life-sciences","tag-plano","tag-plano-headlines","tag-plano-news","tag-secretome-therapeutics"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts\/397782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/comments?post=397782"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts\/397782\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/media\/397783"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/media?parent=397782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/categories?post=397782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/tags?post=397782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"https:\/\/www.newsbeep.com\/us-tx\/wp-content\/uploads\/2026\/08\/Secretome-Therapeutics-Leadership-scaled.jpg\")
<\/p>\n